Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).

Literature DB >> 24430672

The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).

Abstract

Among the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives many of the cancer 'hallmarks' through downstream activation of the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling pathway. Additionally, dysregulation of the interleukin (IL)-6-mediated JAK/STAT3 signaling pathway is closely related to the development of diverse human solid tumors including colorectal cancer (CRC). On this basis, modulation of the IL-6/JAK/STAT3 signaling pathway is currently being widely explored to develop novel therapies for CRC. The present review details the mechanisms and roles of the IL-6/JAK/STAT3 pathway in CRC, describes current therapeutic strategies, and the search for potential therapeutic approaches to treat CRC.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 24430672 DOI： 10.3892/ijo.2014.2259

Source DB: PubMed Journal: Int J Oncol ISSN： 1019-6439 Impact factor: 5.650

Keyword Cloud
Cited

101 in total

1. Constitutive activation of STAT3 and cyclin D1 overexpression contribute to proliferation, migration and invasion in gastric cancer cells.

Authors: Jianfei Luo; Ruicheng Yan; Xiaobo He; Jie He
Journal: Am J Transl Res Date: 2017-12-15 Impact factor: 4.060

2. Loss of the mucosal barrier alters the progenitor cell niche via Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling.

Authors: Liping Zhang; Bradley Turner; Katharina Ribbeck; Kelly G Ten Hagen
Journal: J Biol Chem Date: 2017-11-10 Impact factor: 5.157

Review 3. Hepatitis viruses exploitation of host DNA methyltransferases functions.

Authors: Valerio Pazienza; Concetta Panebianco; Angelo Andriulli
Journal: Clin Exp Med Date: 2015-07-07 Impact factor: 3.984

Review 4. Environmental immune disruptors, inflammation and cancer risk.

Authors: Patricia A Thompson; Mahin Khatami; Carolyn J Baglole; Jun Sun; Shelley A Harris; Eun-Yi Moon; Fahd Al-Mulla; Rabeah Al-Temaimi; Dustin G Brown; Annamaria Colacci; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Roslida A Hamid; Leroy Lowe; Tiziana Guarnieri; William H Bisson
Journal: Carcinogenesis Date: 2015-06 Impact factor: 4.944

5. Laparoscopic surgery minimizes the release of circulating tumor cells compared to open surgery for hepatocellular carcinoma.

Authors: Wenda Li; Xue Zhou; ZeJian Huang; Hongwei Zhang; Lei Zhang; Changzhen Shang; Yajin Chen
Journal: Surg Endosc Date: 2014-12-25 Impact factor: 4.584

6. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.

Authors: Lei Zhang; Qiaoling Song; Xinxin Zhang; Li Li; Ximing Xu; Xiaohan Xu; Xiaoyu Li; Zhuoya Wang; Yuxi Lin; Xin Li; Mengyuan Li; Fan Su; Xin Wang; Peiju Qiu; Huashi Guan; Yu Tang; Wenfang Xu; Jinbo Yang; Chenyang Zhao
Journal: Invest New Drugs Date: 2019-05-14 Impact factor: 3.850

The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).

1. Constitutive activation of STAT3 and cyclin D1 overexpression contribute to proliferation, migration and invasion in gastric cancer cells.

2. Loss of the mucosal barrier alters the progenitor cell niche via Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling.

Review 3. Hepatitis viruses exploitation of host DNA methyltransferases functions.

Review 4. Environmental immune disruptors, inflammation and cancer risk.

5. Laparoscopic surgery minimizes the release of circulating tumor cells compared to open surgery for hepatocellular carcinoma.

6. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.

7. Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines.

8. The DEAD box protein p68: a novel coactivator of Stat3 in mediating oncogenesis.

9. Integrated expression analysis identifies transcription networks in mouse and human gastric neoplasia.

10. Genetic variants in IL-6/JAK/STAT3 pathway and the risk of CRC.